Beth Fand Incollingo

Articles

Everolimus Offers Benefit in Papillary Renal Cell Carcinoma

November 13th 2013

Everolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma, offering promising overall survival results and a tolerable side-effect profile, investigators found in a study presented during the 2013 European Cancer Congress in Amsterdam.

PD-1 and PD-L1 Inhibitors Expected to 'Change the Landscape' of Lung Cancer Treatment

November 11th 2013

The future of PD-1 and PD-L1 inhibition in non-small cell lung cancer is bright, with ongoing studies suggesting that the strategy will lead to a 'new world' in the treatment of the disease

Drug Shortages Persist in Wake of Surveys

November 6th 2013

Headlines from the June meeting of the American Society of Clinical Oncology (ASCO) in Chicago announced to the general public what oncologists and hematologists have known for more than two years: sporadic shortages of cancer drugs are forcing suboptimal treatment plans for patients, and government efforts have not filled the void.

In Advanced Prostate Cancer, Degarelix Offers Advantages Over LHRH Agonists

October 31st 2013

Men with advanced prostate cancer who took the GnRH antagonist degarelix experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events than did those patients who took LHRH agonists.

Leading Immunotherapy Researcher Lands in Qatar

October 25th 2013

Marincola made a bold move earlier this year when he left a longterm position as a tenured senior investigator at the National Institutes of Health (NIH), in Bethesda, Maryland, and moved nearly 7000 miles to the Middle East to build a research program at a private hospital in Qatar.

Pre-Chemo Trial of Enzalutamide Halted After Meeting Endpoints

October 22nd 2013

The phase III PREVAIL trial of enzalutamide in chemotherapy-naÃ¯ve patients with advanced prostate cancer has been stopped early after meeting its co-primary endpoints of overall survival and radiographic progression-free survival

First Approved Alpha Emitter Bolsters Arsenal Against Prostate Cancer

October 10th 2013

With the recent approval of a first-in-class radioactive isotope as a treatment for prostate cancer, urologists have a new weapon in their rapidly growing arsenal of therapies designed to fight this disease.

Alvarez Plays Leadership Role in Gynecologic Cancer Field

September 20th 2013

Whether it involves the minutiae of preclinical studies or the broad perspective of group leadership, if the work concerns gynecologic oncology, Ronald D. Alvarez, MD, has likely tried it.

Herbal Supplement Could Outperform Observation in Some Patients With Recurrent Prostate Cancer

September 18th 2013

A cocktail of herbs and vitamins lowered PSA in more than a third of patients with biochemically recurrent prostate cancer, and thus may be a good alternative to observation in this population.

Rugo Offers Window Into Evolving Views of ER-Positive Disease

September 6th 2013

Research efforts are under way to improve the efficacy of hormone therapy in the management of advanced estrogen receptor-positive (ER) breast cancer, including new strategies for targeting the PI3K/ mTOR pathway.

Analyzing the Nuances of Trastuzumab Therapy for HER2-Positive Breast Cancer

September 3rd 2013

Trastuzumab is the clear standard of care for firstline therapy for nearly all HER2-positive breast cancers, and the oncology community has come a long way toward understanding how best to use the drug.

Preclinical Studies Yield New Pathway Clues in Medulloblastoma

August 28th 2013

Since the mid-1970s, Rakesh K. Jain, PhD, has pursued an interest in the role that tumor microenvironment plays in drug delivery and efficacy.

TNBC Studies Yield Clues for Future Directions

August 27th 2013

Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer, but studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.

Exploring Tumors in Context: Jain's Work Blazes Trail on Microenvironment

August 16th 2013

An interview with Rakesh K. Jain, PhD, a cancer researcher focused on pathophysiology who helped establish the role of the tumor microenvironment in the treatment of cancer.

Navigation Program Proves a Win-Win for Patients and Medical Center

August 14th 2013

A grant from a pharmaceutical company is translating into a win for both the University Medical Center of Princeton at Plainsboro and its patients with cancer.

CTC-Based Biomarkers Can Be Measured for Sensitivity to Novel Breast Cancer Drug

August 9th 2013

Biomarkers for sensitivity to etirinotecan pegol that are found in circulating tumor cells of breast cancer patients can be "reliably measured."

Holland's Research Focuses on Needs of Older Patients

July 25th 2013

When Jimmie C. Holland, MD, conducts research, geriatric cancer patients are often her focus. Holland has studied telephone intervention as a way to monitor stress in patients aged 65 and older. She discussed the effort with OncologyLive.

On the Frontier of Cancer Care: Holland Helped Pioneer Psychosocial Treatment

July 19th 2013

An Interview With Jimmie C. Holland, MD, on her research and role in the development of a vital area of cancer care.

Nurses Have Key Role in Managing Side Effects of Maintenance Therapy

June 27th 2013

More and more, as the use of maintenance therapy increases, oncology nurses are tasked with monitoring how the strategy is working for specific patients.

Charting the Course in Myeloma: Durie Keeps Standards, New Goals in Sight

June 10th 2013

As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn't save who have most affected his path.